Oruka Therapeutics Announces $200 Million Private Placement
Oruka Therapeutics, Inc. (ORKA)
Company Research
Source: GlobeNewswire
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $200 million to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including a large investment manager, Braidwell LP, Venrock Healthcare Capital Partners, Fairmount, Access Biotechnology, Blackstone Multi-Asset Investing, Frazier Life Sciences, Paradigm BioCapital, RTW Investments LP, SR One, Janus Henderson Investors, Commodore Capital, Kalehua Capital, Avidity Partners, Affinity Healthcare Fund LP and Allostery Investments L
Show less
Read more
Impact Snapshot
Event Time:
ORKA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORKA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORKA alerts
High impacting Oruka Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ORKA
News
- Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology CongressGlobeNewswire
- Oruka Therapeutics, Inc. (NASDAQ: ORKA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $44.00 price target on the stock.MarketBeat
- Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $41.00 price target on the stock.MarketBeat